Virus three times deadlier than flu, oximeters less reliable on Black
patients
Send a link to a friend
[December 19, 2020]
By Nancy Lapid
(Reuters) - The following is a roundup of
some of the latest scientific studies on the novel coronavirus and
efforts to find treatments and vaccines for COVID-19, the illness caused
by the virus.
COVID-19 far more deadly than seasonal flu
COVID-19 is three times more deadly than seasonal influenza, according
to researchers in France who compared 89,530 patients hospitalized with
COVID-19 early this year with 45,819 patients hospitalized with flu
between December 2018 and February 2019. The death rate was 16.9% vs
5.8%, which is "particularly striking when reminded that the 2018/2019
flu season had been the worst in the past five years in France in terms
of number of deaths," Dr. Catherine Quantin, from Dijon University
Hospital, said in a news release. More patients with COVID-19 landed in
intensive care units (16.3% vs 10.8%) and the average ICU stay was
nearly twice as long (15 days vs 8 days), her team reported on Thursday
in The Lancet Respiratory Medicine. COVID-19 patients were also more
likely to need mechanical ventilation and to suffer lung failure. In
another study published on Wednesday in The BMJ, U.S. researchers found
people being hospitalized for COVID-19 carried higher risks of organ
failure and death, and increased health resource use, compared to people
hospitalized for the flu.
Oxygen-monitoring devices less reliable in Black patients
COVID-19 can cause blood oxygen levels to fall to dangerously low
levels, and devices used to monitor these levels are far less reliable
in Black patients than in white patients, a large study found. So-called
pulse oximeters clip onto a fingertip and pass red and infrared light
through the skin to gauge oxygen levels in the blood, which darkens when
levels drop. Because pulse oximeters were mostly tested on whites when
they were developed, they are calibrated for people with light skin.
Among 1,609 patients studied this year at the University of Michigan
Hospital in Ann Arbor, the devices missed low oxygen levels in 11.7% of
Black patients compared to 3.6% of white patients. When the researchers
studied another 8,392 patients treated at 178 intensive-care units in
2014-2015, they found pulse oximeters missed low oxygen levels in 17.0%
of Blacks versus 6.2% of whites. "Given the widespread use of pulse
oximetry for medical decision-making, these findings have some major
implications, especially during the current COVID-19 pandemic," the
researchers warned on Wednesday in The New England Journal of Medicine.
"Reliance on pulse oximetry to triage patients and adjust supplemental
oxygen levels may place Black patients at increased risk."
[to top of second column]
|
Healthcare worker Maria Meza wears personal protective equipment as
she measures blood sugar levels of a coronavirus disease (COVID-19)
positive patient at Medical Arts Hospital in Lamesa, Texas, U.S.,
December 17, 2020. REUTERS/Go Nakamura
Minority COVID-19 patients may benefit from tocilizumab
Among mostly non-white patients hospitalized with COVID-19
pneumonia, Roche's arthritis drug Actemra, also known as tocilizumab,
reduced the odds of needing mechanical ventilation or dying. Among
the 389 volunteers in a study, the combined risk of those events was
12% in patients randomly assigned to receive tocilizumab in addition
to standard care, versus 19% in those who received a placebo.
Looking only at the risk of death, however, rates in the two groups
were similar, researchers reported on Thursday in The New England
Journal of Medicine. Tocilizumab also did not hasten patients'
discharge from the hospital or the time it took for their medical
status to improve. Previous studies did not focus on racial or
ethnic minorities and yielded mixed results. Earlier this month, a
different team of doctors reported that the drug reduced patients'
risk of dying in the hospital, but the difference was not
statistically significant. The Infectious Diseases Society of
America currently does not recommend routine use of tocilizumab in
hospitalized patients.
(Reporting by Nancy Lapid, Megan Brooks and Gene Emery; Editing by
Tiffany Wu)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|